Authors
Loading...
Preclinical evaluation demonstrates superior efficacy of KAT6i with PI3K inhibitors in ER+ breast cancer, suggesting new treatment options.
Bhat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: